$11 per pen, $55 for a month's supply of this long lasting insulin. It has been a long road to get here. This is a process that has unfolded over the course of the last three years. and it's a process that will continue to unfold over the next few years as we expand the portfolio of options as it relates to insulin, our partnership with biocon and continue our effort to expand the portfolio of opportunities under this CalRx brand. (12:24–12:28)
CLAIM
Asserts that the process to provide lower-cost insulin has taken three years.
This is an excerpt from a raw transcript. The assertions have not been audited or verified. Tap the video to view the source footage and understand the context.